FTSE 100 news / Companies and sectors / Pharma and healthcare / 6 October 2026
Pharma and healthcare: sector news on Tuesday 6 October 2026
Average tone +3.2 (positive) across 5 companies with relevant coverage, from 59 stories.
Company by company
| Company | Tone | Stories | What the coverage was about |
|---|---|---|---|
| AstraZeneca | +6.8 | 37 | Coverage was dominated by the opening of AstraZeneca's $1bn R&D centre in Cambridge, Massachusetts, with hiring plans. |
| Haleon | −5.7 | 7 | Coverage was mainly about JPMorgan cutting its price target on Haleon from 315p to 295p and placing it on negative watch ahead of Q3 results. |
| GSK | +4.7 | 6 | Coverage was mildly positive, led by a Health Canada review of Jemperli for rectal cancer, a ViiV investment in paediatric HIV response and discussion of the Nuvalent acquisition as a growth prospect. |
| Smith & Nephew | +4.0 | 5 | Coverage centred on product news, with regulatory clearance for the LANDMARK knee system and the launch of the EVOS system. |
| Convatec | +6.3 | 4 | Coverage centred on the launch of Cure Aqua in North America and a new CEO's plan to push R&D after a long turnaround. |
Strongest stories in the sector
- +8.7 Does FTSE 100 Medtech (LSE:SNN) Gain A Fresh Orthopaedics Catalyst From Its LANDMARK Knee System Clearance?
LANDMARK knee system clearance is a fresh orthopaedics catalyst. - +7.5 AstraZeneca to invest over $1 billion in Massachusetts, boost workforce
Over $1bn Massachusetts investment, more workforce - +7.5 ‘We’re here at the party now:’ AstraZeneca opens new Kendall hub with big hiring plans
New Kendall hub with big hiring plans - +7.5 AstraZeneca to invest over US$1bil in Massachusetts, boost workforce
Over $1bn Massachusetts investment and hiring - +7.5 GSK’s Jemperli (dostarlimab) accepted for review by Health Canada for patients with dMMR/MSI-H locally advanced rectal cancer
Health Canada accepted Jemperli rectal cancer application for review - +7.2 AstraZeneca opens new global strategic R&D centre in Kendall Square, Cambridge, Massachusetts
Company announces new strategic R&D centre - +7.2 AstraZeneca opens $1 billion R&D center in Kendall Square
Opens $1bn R&D centre in Kendall Square - +7.2 AstraZeneca opens new Massachusetts R&D center as part of $1 billion investment
New R&D centre in $1bn investment - +7.2 AstraZeneca to Invest Over $1 Billion in Massachusetts
Over $1bn Massachusetts investment - +7.2 AstraZeneca to invest over $1B in Massachusetts ops
Over $1bn Massachusetts investment - +7.2 AstraZeneca opens $1B R&D center in Cambridge, Massachusetts By Investing.com
Opens $1bn R&D centre in Cambridge - +7.2 AstraZeneca opens $1B R&D center in Cambridge, Massachusetts
Opens $1bn R&D centre in Cambridge
Pharma and healthcare: every day · FTSE 100 overview for the day